Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Chronic Spontaneous Urticaria 

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Spot Test

Editorial Advisory Board

Partners

Subscribe

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Articles

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times: August 14, 2025

Walter Liszewksi, MD, is a board-certified dermatologist and associate professor of dermatology at the Northwestern Feinberg School of Medicine in Chicago, Illinois.

Videos

Walter Liszewski, MD, discusses the personalized and evolving treatment landscape for moderate to severe AD, emphasizing a tailored approach using new biologics and non-steroidal topicals to meet individual patient needs and expectations.

Tailoring Treatment for Atopic Dermatitis Beyond Steroids

Irina Mazur spoke to Dermatology Times about the latest partnership, which aims to bridge the gap between clinical advice and patient behavior through personalized sun protection guidance.

Q&A: Bringing Dermatologist Expertise to Everyday Sun Care with SunSolve MD and Revieve

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and received her Masters in Digital Media from Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family. 

Andrade's inspiring journey highlights the challenges of HS and the transformative impact of clinical trials.

Living Evidence: Long-Term Benefits of HS Clinical Trial Enrollment

Dermatology Times connects dermatology professionals with key skin disorder coverage, therapeutic strategies, clinical trial updates, and expert insights.

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times - Dermatology News and Clinical Insights

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

Chaquira Andrade is a patient advocate for hidradenitis suppurativa. She was involved in the clinical trial leading to the 2024 approval of bimekizumab for HS, and speaks about her journey both online and at dermatologic meetings.

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

I'm sorry, but it seems there is no article text provided for me to summarize and extract key takeaways from. Could you please provide the text of the article

Polls 

POLL: What is the Most Common Type of Mole Found on Adults? 

Nemolizumab, a monoclonal antibody targeting the interleukin-31 receptor A (IL-31RA), has emerged as an important therapy for atopic dermatitis (AD) patients with moderate to severe pruritus.

 While its antipruritic efficacy is well established, new concerns have arisen regarding its association with distinct cutaneous manifestations.

 A recent Japanese multicenter retrospective study by Sasaki et al, published in

, offers valuable clinical insights into the incidence, morphology, and potential risk factors for these adverse skin events in real-world settings.

The study evaluated 219 patients aged ≥13 years with clinically diagnosed AD who received at least 1 dose of nemolizumab across 13 Japanese institutions between August 2022 and February 2024. Patients receiving fewer than 3 doses without any skin reactions were excluded to avoid misclassification of late-onset manifestations. Clinical features and laboratory markers were compared between patients with and without cutaneous adverse events.

It is worth noting that dosage regulations in Japan differ from those in the US, with this study in particular following international guidelines. These data represent patients being dosed 60 mg every 4 weeks, rather than an initial 60 mg dose followed by 30 mg every 4 weeks as is approved by the US FDA.

Researchers found cutaneous manifestations occurred in 88 patients (40.2%), typically within the first 3 doses. Erythema was the most prevalent eruption (69.3%), followed by coin-shaped red plaques with exudate (42.0%), dry/scaly lesions (29.5%), papules (21.6%), edema (10.2%), and vesicles (6.8%). Most eruptions (64.3%) were non-pruritic. Importantly, these manifestations were distinguished from exacerbations of baseline AD by clinical morphology and timing.

Two patients developed bullous pemphigoid, according to the study, confirmed by serologic and histopathologic testing, indicating a potential for nemolizumab to trigger autoimmune skin conditions in susceptible individuals.

The study found roughly 80% of cutaneous reactions emerged within the first 3 doses, with a significant drop in incidence after the sixth dose. The forearms, back, upper arms, and lower legs were the most frequently affected initial sites, suggesting a non-random distribution pattern that could aid early recognition.

Despite the high incidence of reactions, 58% of affected patients continued nemolizumab therapy, typically managed with high-potency topical corticosteroids. The median duration of eruptions was 27 days for those who continued therapy and 33 days for those who discontinued, researchers stated, with no statistically significant difference. This suggests that stopping treatment does not necessarily lead to quicker resolution of symptoms.

The study found no significant associations between cutaneous manifestations and baseline disease severity (measured by EASI), eosinophil counts, serum IgE, or thymus and activation-regulated chemokine (TARC) levels.

These findings suggest that nemolizumab-induced eruptions may arise independently of known markers of AD severity or systemic inflammation. The absence of predictive biomarkers complicates efforts to stratify risk, emphasizing the need for close clinical observation early in treatment.

The study stated the distinct, often non-pruritic nature of these eruptions, coupled with their early onset and morphological variation, points toward a pharmacologic rather than disease-related mechanism. IL-31 is known to modulate neuroimmune interactions, and its blockade may disrupt regulatory feedback loops, possibly unleashing unchecked type 2 inflammation or unmasking latent autoimmunity.

For clinicians, awareness of these potential adverse effects is crucial for patient counseling and early management. Mild to moderate eruptions can typically be managed with intensified topical therapy, allowing for continued treatment. In severe cases, discontinuation may be necessary, but resolution should not be expected immediately due to nemolizumab's long half-life and prolonged pharmacodynamic effects.

Close monitoring during the initial dosing period—particularly up to the third dose—is advisable, according to researchers, and clinicians should be prepared to adjust treatment based on morphological patterns of eruptions rather than systemic biomarkers.

Nemolizumab is effective in controlling pruritus in AD, however some patients may experience distinct cutaneous reactions, often within the early phases of therapy. These reactions appear to be mechanistically independent of disease severity and immune status and can generally be managed with topical corticosteroids without discontinuing treatment. However, the absence of predictive markers highlights the importance of clinical vigilance and underscores the need for future research into the immunopathogenesis of these events.

Igarashi A, Katsunuma T, Nagano Y, Komazaki H. Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study. 

. 2025;192(5):837-844. doi:10.1093/bjd/ljae458

Masuda T, Yonekura S, Kataoka K, et al. Psoriasis-like lesions in an atopic dermatitis patient possibly associated with nemolizumab treatment. 

. 2024;51(6):e193-e195. doi:10.1111/1346-8138.17085

Katsuta M, Kamide R, Ishiuji Y, Nobeyama Y, Asahina A. Bullous pemphigoid that developed during nemolizumab treatment for atopic dermatitis: Two case reports. 

 2024;104:adv40634. Published 2024 Sep 2. doi:10.2340/actadv.v104.40634

Sasaki W, Saito R, Suzuki K, et al. Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: A multicenter retrospective study in Japan. 

 Published online July 23, 2025. doi:10.1111/1346-8138.17877

Nemolizumab, a monoclonal antibody targeting IL-31RA, is effective for atopic dermatitis patients with moderate to severe pruritus. However, it is associated with distinct cutaneous manifestations, occurring in about 40% of patients, typically within the first three doses. These eruptions, often non-pruritic, are morphologically distinct from baseline AD exacerbations. The study found no significant correlation between these reactions and baseline disease severity or systemic inflammation markers. Management usually involves topical corticosteroids, and discontinuation of nemolizumab does not necessarily expedite symptom resolution.

The Japanese study found no association between cutaneous events and baseline EASI scores, eosinophil counts, or IgE levels.

Patterns of Cutaneous Reactions to Nemolizumab in AD

' Weekly Crossword, where dermatology knowledge meets fun! Each week, we curate a selection of words and terms pulled directly from the latest news in the dermatology world. Whether it's breakthrough treatments, new research findings, or emerging trends, this crossword serves as both a challenge and an opportunity to reinforce your expertise in the field.

This week's special edition of the Dermatology Times crossword focuses on he recent approval of delgocitinib for adults with moderate to severe CHE who have not responded adequately to prior topical corticosteroids or for whom corticosteroid use is not advisable.

For more in-depth insights, don't forget to check out our Weekly Roundup, where we break down the most important stories and updates from the past week. And to stay ahead of the curve and prepare for future crosswords, make sure to follow our content throughout the week.

Try out either our interactive crossword or a static/non-interactive version below.

Top country involved in the DELTA trials besides the US.

Delgocitinib inhibits how many JAK isoforms?

This clinical trial assessed long-term safety and efficacy of delgocitinib.

This condition is characterized by relapsing or persistent hand eczema for more than 3 months.

This dermatologist called delgocitinib “a first-in-class topical therapy poised to simplify our approach to CHE.”

Brand name of delgocitinib cream approved for CHE in 2025.

According to Gooderham et al. 2025, what was the most common non-infectious adverse event reported during DELTA 3?

This JAK inhibitor is the first topical treatment FDA-approved for CHE.

Patients with which two IGA-CHE scores were not treated during DELTA 3 unless relapse occurred? (Answer format: “__ or __”)

The severity of CHE was assessed using this index.

First region outside the US where delgocitinib was approved.

Delgocitinib cream is applied how many times per day?

The 2025 medical meeting where post hoc data on delgocitinib was presented.

This symptom, alongside pain, was significantly reduced by delgocitinib.

This metric measured treatment success in the DELTA trials.

Delgocitinib, a JAK inhibitor, has been approved for adults with moderate to severe chronic hand eczema (CHE) who have not adequately responded to topical corticosteroids or cannot use them. The DELTA trials, including DELTA 3, assessed its long-term safety and efficacy. Delgocitinib inhibits multiple JAK isoforms and is the first FDA-approved topical treatment for CHE. The brand name for the cream will be released in 2025. The treatment significantly reduces symptoms like itching and pain, with the most common non-infectious adverse event being dermatitis.

Test your knowledge of key words and terms associated with the recent approval of delgocitinib for adults with moderate to severe CHE.

Quizzes

Dermatology Times' Weekly Crossword: August 10, 2025

To stay informed with the latest conference insights,

2025 Society for Pediatric Dermatology (SPD) Annual Meeting 

wrapped up with a strong emphasis on innovation, global perspectives, and community updates, offering attendees both clinical pearls and future-forward tools to bring back to their practices.

The morning kicked off with updates from the American Board of Dermatology and Pediatric Dermatology subspecialty leadership. Julie Schaffer, MD, and Andrea Zaenglein, MD, provided attendees with the latest information on board certification, evolving practice standards, and how the specialty continues to grow in response to changing health care needs.

This was followed by a brief awards presentation, recognizing outstanding contributions in research, service, and mentorship across the field.

Continuing a popular tradition throughout the meeting, Luke Johnson, MD, returned for a third installment of Hot Topics & Trends in Pediatric Dermatology, delivering a snapshot of the latest developments in diagnostics, therapies, and care delivery models.

One of the standout sessions of the day was the second installment of the Hurwitz Lecture, where Angela Hernandez Martin, MD, returned to the podium to present Pediatric Dermatology Reimagined: The Game-Changing Tool of Ultrasound. With practical insights and case examples, Hernandez Martin outlined how high-frequency ultrasound is transforming diagnostic accuracy and non-invasive monitoring in pediatric patients, particularly in complex skin and soft tissue conditions.

Eichenfield Urges Lifelong Learning Amid Evolving Treatment Landscape

The morning continued with 2 focused talks. Molly Youssef, MD, of the Mayo Clinic, explored the often-overlooked realm of mucosal disease in pediatric populations, offering guidance on early recognition and multidisciplinary management. James Bennett, MD, PhD, followed with a discussion on the application of genetic testing in vascular anomalies clinics, highlighting how genomic advances are leading to more targeted diagnoses and personalized treatment pathways.

Following a mid-morning break and poster viewing session, the program resumed with a series of brief but impactful updates. Carrie Coughlin, MD, MPHS, shared highlights from the latest PeDRA (Pediatric Dermatology Research Alliance) meeting, emphasizing collaborative research priorities and funding opportunities. James Treat, MD, then offered a snapshot of discussions from the recent World Congress of Pediatric Dermatology, underscoring global initiatives and cross-border partnerships in improving pediatric skin health.

As the meeting began to wind down, Solveig Ophaug, MD, and Rachel Dunlap, MD, delivered the Pediatric Dermatology Year in Review, synthesizing key studies, therapeutic advancements, and practice-changing evidence published over the past year.

Finally, SPD closed its 2025 meeting with part 2 of Sam Weinberg’s Cases of the Year, an attendee favorite. As in previous sessions, expert faculty presented unusual or diagnostically challenging cases that sparked lively discussion and illustrated the importance of curiosity, collaboration, and clinical rigor in pediatric dermatology.

With 3 days of robust programming, powerful tributes, and dynamic conversations, SPD 2025 concluded on a high note—equipping clinicians with the tools, insights, and connections needed to shape the future of the specialty.

keep up to date with the latest in coverage from the conference

The 2025 Society for Pediatric Dermatology Annual Meeting concluded with a focus on innovation, global perspectives, and community updates. Key sessions included updates on board certification, evolving practice standards, and the use of high-frequency ultrasound in diagnostics. Presentations covered mucosal disease management, genetic testing in vascular anomalies, and collaborative research priorities. The meeting highlighted global initiatives and partnerships, and concluded with a review of significant studies and challenging cases. Attendees left equipped with new tools, insights, and connections to advance pediatric dermatology.

Catch up on coverage from the third day of the 50th Annual Society for Pediatric Dermatology Meeting in Seattle, Washington.

Day 3 Recap: 50th Annual SPD Dermatology Conference 2025

offered a rich blend of celebration, education, and reflection, as attendees honored trailblazers in the field while examining evolving clinical, research, and practice-based themes.

The sessions opened with the presentation of the AAP Alvin Jacobs Award, recognizing Lawrence Schachner, MD, for his distinguished contributions to pediatric dermatology. Teresa Wright, MD, presented the award, highlighting Schachner’s legacy in both patient care and mentorship. This was followed by brief announcements and another round of Hot Topics & Trends in Pediatric Dermatology from Luke Johnson, MD.

Lawrence Schachner, MD, Reflects on Career, Mentorship, and Innovation

Next, Ginna Sybert, MD, was inducted into the SPD Hall of Fame, presented by Melinda Jen, MD. Sybert was honored for her impact on the field through clinical genetics and mentorship.

The morning’s clinical centerpiece was the Cases in Search of a Diagnosis Panel, where a powerhouse lineup of experts—including Ilona Frieden, MD, and Antonio Torrelo, MD—walked attendees through complex patient scenarios with elusive or evolving diagnoses. The collaborative session showcased the value of group wisdom in unraveling diagnostic mysteries.

Following this, Dawn Siegel, MD, provided updates from the SPD Year in Review, including highlights from the compensation survey results, giving members data-driven insights into workforce trends.

A highlight of the morning was a special session marking SPD’s 50th anniversary, framed through the legacy of the late Robert Sidbury, MD. Moderated by Markus Boos, MD, and Heather Brandling-Bennett, MD, the panel brought together leaders such as Amy Paller, MD, and Peter Lio, MD, to reflect on Sidbury’s contributions and the broader evolution of pediatric dermatology. The conversation offered a moving tribute and an inspiring vision for the future of the specialty.

Robert Sidbury, MD, MPH, Leaves a Lasting Legacy in Pediatric Care

Following time for poster viewing, the program resumed with 3 targeted lectures. Jennifer Huang, MD, outlined what pediatric dermatologists need to know about Graft-Versus-Host Disease, while Harper Price, MD, presented on the management of congenital melanocytic nevi. Sarah Coates, MD, then delivered a thoughtful talk on the impact of social determinants of health in clinical dermatology, challenging attendees to consider systemic influences on care and outcomes.

The Research Panel, featuring Cory Simpson, MD, PhD, Keith Choate, MD, PhD, and Anna Cristina Garza-Mayers, MD, PhD, rounded out the morning with updates on novel investigations and translational science in dermatology.

The afternoon wrapped up with breakout sessions tailored to diverse interests and career stages. Topics ranged from practical tips for inbox management and EHR efficiency (led by Mimi Cabrera, MD) to resilient communication, leadership strategies for section chiefs, and a social media workshop titled In the Spotlight: Mastering Media, Messaging, and Social Media. An Advanced Practice Provider-focused session on biologics and targeted therapies, led by Aditi Murthy, MD, also underscored SPD’s commitment to inclusive, multidisciplinary education.

Lisa Swanson, MD, FAAD, Highlights Expanding Pediatric Treatment Options

With a focus on both honoring the past and preparing for the future, Friday’s sessions reinforced SPD 2025’s central themes: community, clinical excellence, and forward-thinking innovation.

Day 2 of the 2025 Society for Pediatric Dermatology Annual Meeting celebrated leaders in pediatric dermatology while exploring clinical, research, and practice-based themes. Lawrence Schachner, MD, received the AAP Alvin Jacobs Award, and Ginna Sybert, MD, was inducted into the SPD Hall of Fame. The event featured a diagnostic panel, updates on workforce trends, and a tribute to Robert Sidbury, MD. Sessions covered topics like Graft-Versus-Host Disease, congenital melanocytic nevi, and social determinants of health, concluding with breakout sessions on diverse professional interests.

Catch up on coverage from the second day of the 50th Annual Society for Pediatric Dermatology Meeting in Seattle, Washington.

Chaquira Andrade, Patient Advocate

Articles

Latest Updated Articles